Literature DB >> 8465872

Trends in the prescription of antidepressants by office-based psychiatrists.

M Olfson1, G L Klerman.   

Abstract

OBJECTIVE: This study was done in an effort to determine whether there was a change over the past decade in the number and proportion of patients prescribed antidepressants by psychiatrists in private practice.
METHOD: The authors analyzed data from the National Ambulatory Medical Care Survey for the years 1980, 1985, and 1989, focusing on visits by adults over the age of 18 years to physicians specializing in psychiatry and psychiatric subspecialties.
RESULTS: The number of visits that included prescribing an antidepressant medication grew from approximately 2.5 million in 1980 to 4.7 million in 1989, or from 17.9% to 30.4% of all office-based psychiatric visits. Fluoxetine, which first became available in 1988, accounted for 29.6% of the prescriptions for antidepressants in 1989. Increases in prescriptions for antidepressants were particularly evident for male patients, young adult patients, and patients with neurotic disorders.
CONCLUSIONS: There was an increase in the 1980s in the use of antidepressants in office-based psychiatric practice. The advent of new agents and the broadening of the clinical usefulness of existing agents may have contributed to this increase.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8465872     DOI: 10.1176/ajp.150.4.571

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  10 in total

Review 1.  Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice.

Authors:  M J Burke; S H Preskorn
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

2.  The role of monoamine oxidase inhibitors in current psychiatric practice.

Authors:  Jess G Fiedorowicz; Karen L Swartz
Journal:  J Psychiatr Pract       Date:  2004-07       Impact factor: 1.325

Review 3.  The economics of selective serotonin reuptake inhibitors in depression: a critical review.

Authors:  L Frank; D A Revicki; S V Sorensen; Y C Shih
Journal:  CNS Drugs       Date:  2001-01       Impact factor: 5.749

Review 4.  The need for an iterative process for assessing economic outcomes associated with SSRIs.

Authors:  T L Skaer; D A Sclar; L M Robison; R S Galin
Journal:  Pharmacoeconomics       Date:  2000-09       Impact factor: 4.981

5.  Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis.

Authors:  Neil Risch; Richard Herrell; Thomas Lehner; Kung-Yee Liang; Lindon Eaves; Josephine Hoh; Andrea Griem; Maria Kovacs; Jurg Ott; Kathleen Ries Merikangas
Journal:  JAMA       Date:  2009-06-17       Impact factor: 56.272

6.  Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.

Authors:  Ya-Chen Tina Shih; Nebiyou B Bekele; Ying Xu
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

7.  A comparative survey of antidepressant drug prescribing habits of general practitioners and psychiatrists.

Authors:  M Lapeyre-Mestre; K Desboeuf; I Aptel; J J Chale; J L Montastruc
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

8.  Comparative effectiveness of medication versus cognitive-behavioral therapy in a randomized controlled trial of low-income young minority women with depression.

Authors:  Juned Siddique; Joyce Y Chung; C Hendricks Brown; Jeanne Miranda
Journal:  J Consult Clin Psychol       Date:  2012-10-22

9.  Antidepressant use and diabetes mellitus risk: a meta-analysis.

Authors:  Jae Moon Yoon; Eun-Geol Cho; Hyun-Ki Lee; Sang Min Park
Journal:  Korean J Fam Med       Date:  2013-07-24

10.  Prescribing practices in the treatment of depression among psychiatrists in Oman.

Authors:  Marwa A Albalushi; Mandhar H Almaqbali; Salim K Al-Huseini; Hamed N Alsinawi
Journal:  Neurosciences (Riyadh)       Date:  2021-04       Impact factor: 0.906

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.